Share Price and Basic Stock Data
Last Updated: October 10, 2025, 1:46 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Hindustan Agrigenetics Ltd operates within the floriculture industry, focusing on the cultivation and distribution of flowers and ornamental plants. The company’s revenue has shown significant fluctuations over recent quarters, with reported sales of ₹0.04 Cr in June 2023 and again in June 2024, while it recorded ₹0.03 Cr in December 2022 and December 2023. However, the overall sales trend indicates a stagnant performance, with total sales for the fiscal year ending March 2025 standing at ₹0.08 Cr, a slight increase from ₹0.07 Cr in the previous year. The company’s expenses have surged, reaching ₹1.10 Cr in FY 2025, which severely impacted its operating profitability, leading to an operating profit margin (OPM) of -1,275.00% for the same period. This negative margin reflects a challenging business environment where revenues have not kept pace with rising costs, underscoring the need for operational efficiency improvements.
Profitability and Efficiency Metrics
Profitability metrics for Hindustan Agrigenetics Ltd reveal a concerning trend. The company reported a net profit of -₹0.31 Cr for FY 2025, down from a net profit of ₹0.47 Cr in FY 2024. This decline is compounded by a negative return on equity (ROE) of -2.53% and a return on capital employed (ROCE) of -3.53%, indicating that the company is not effectively utilizing its capital to generate profits. The interest coverage ratio stood at -23.78x, suggesting that the company is unable to cover its interest obligations, which poses a significant risk to its financial stability. The cash conversion cycle remained at 0.00 days, indicating no operational efficiency in converting inventory into cash flow. Furthermore, the company’s operating profit has consistently been negative over the past few years, with an operating profit margin that has reached alarming levels, highlighting severe operational challenges within the business.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hindustan Agrigenetics Ltd exhibits a mixed picture. As of March 2025, the company reported reserves of ₹7.62 Cr, which is a positive indicator of retained earnings. However, the absence of borrowings (₹0.00 Cr) reflects a possible lack of leverage, which may limit growth opportunities. The price-to-book value (P/BV) ratio is 2.46x, suggesting that the market values the company higher than its book value, which could indicate investor confidence despite underlying operational issues. The current ratio of 330.73x and quick ratio of 330.73x indicate exceptional liquidity, but such high ratios are often unsustainable and may imply inefficient use of assets. The enterprise value has increased to ₹24.41 Cr, reflecting a growing valuation despite the company’s performance challenges. These financial ratios suggest that while the company maintains a solid liquidity position, its profitability and operational efficiency require urgent attention.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hindustan Agrigenetics Ltd shows a significant shift in ownership dynamics. Promoter holdings have declined from 29.42% in September 2022 to 8.18% by June 2025, suggesting a potential loss of confidence from the founding members. Conversely, public shareholding has increased to 81.89%, indicating that retail investors are now the dominant stakeholders, which can be both a strength and a risk. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) account for a mere 0.43% and 1.08%, respectively, which reflects limited institutional interest in the company. The number of shareholders has increased to 7,454, showcasing a growing retail investor base. However, the declining promoter stake may raise concerns about the long-term vision and commitment of the original founders, which could affect future investor confidence.
Outlook, Risks, and Final Insight
If margins sustain their current trajectory, the company may continue to face substantial operational challenges that could hinder growth. The significant rise in expenses, coupled with stagnant sales, poses a serious risk to profitability. Additionally, the declining promoter stake raises concerns about governance and strategic direction. However, if Hindustan Agrigenetics can improve its operational efficiency and manage costs effectively, it may turn around its financial performance. The current liquidity position provides a buffer for the company to explore growth opportunities or invest in efficiency-enhancing measures. Moreover, increasing public interest may offer a platform for potential capital infusion. Nonetheless, the company must address its operational inefficiencies and improve profitability metrics to enhance its overall market position and restore investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hindustan Agrigenetics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Nagarjuna Agri Tech Ltd | 43.8 Cr. | 46.7 | 83.3/28.3 | 7.19 | 0.00 % | 1.34 % | 1.34 % | 10.0 | |
| Hindustan Agrigenetics Ltd | 27.5 Cr. | 62.6 | 103/47.4 | 688 | 0.00 % | 3.53 % | 3.61 % | 10.0 | |
| Elegant Floriculture & Agrotech (India) Ltd | 14.1 Cr. | 5.50 | 11.6/4.38 | 4.73 | 9.16 | 0.00 % | 5.85 % | 5.22 % | 10.0 |
| Industry Average | 0 Cr | 38.27 | 346.37 | 8.18 | 0.00% | 3.57% | 3.39% | 10.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 | 0.00 | 0.03 | 0.00 | 0.04 |
| Expenses | 0.33 | 0.05 | 0.11 | 0.12 | 0.03 | 0.07 | -0.06 | 0.01 | 0.01 | 0.00 | 0.24 | 0.69 | 0.14 |
| Operating Profit | -0.29 | -0.05 | -0.08 | -0.12 | 0.01 | -0.07 | 0.09 | -0.01 | 0.03 | 0.00 | -0.21 | -0.69 | -0.10 |
| OPM % | -725.00% | -266.67% | 25.00% | 300.00% | 75.00% | -700.00% | -250.00% | ||||||
| Other Income | 0.09 | 0.14 | 0.15 | 0.03 | 0.14 | 0.16 | 0.15 | 0.15 | 0.02 | 0.15 | 0.24 | 0.18 | 0.51 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | -0.20 | 0.09 | 0.07 | -0.09 | 0.15 | 0.08 | 0.23 | 0.13 | 0.04 | 0.14 | 0.02 | -0.52 | 0.40 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.20 | 0.09 | 0.07 | -0.09 | 0.15 | 0.07 | 0.22 | 0.13 | 0.04 | 0.14 | 0.02 | -0.52 | 0.40 |
| EPS in Rs |
Last Updated: August 19, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Hindustan Agrigenetics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.04 Cr., marking an increase of 0.04 Cr..
- For Expenses, as of Jun 2025, the value is 0.14 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.69 Cr. (Mar 2025) to 0.14 Cr., marking a decrease of 0.55 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.10 Cr.. The value appears strong and on an upward trend. It has increased from -0.69 Cr. (Mar 2025) to -0.10 Cr., marking an increase of 0.59 Cr..
- For OPM %, as of Jun 2025, the value is -250.00%. The value appears to be declining and may need further review. It has decreased from 0.00% (Mar 2025) to -250.00%, marking a decrease of 250.00%.
- For Other Income, as of Jun 2025, the value is 0.51 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Mar 2025) to 0.51 Cr., marking an increase of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.52 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.92 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.52 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.92 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.00. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 12:57 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.19 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.07 |
| Expenses | 0.12 | 0.26 | 0.12 | 0.16 | 0.21 | 0.22 | 0.59 | 0.19 | 0.23 | 0.71 | 0.39 | 1.10 | 1.07 |
| Operating Profit | -0.06 | -0.20 | -0.06 | -0.10 | -0.16 | -0.16 | -0.40 | -0.13 | -0.17 | -0.64 | -0.32 | -1.02 | -1.00 |
| OPM % | -100.00% | -333.33% | -100.00% | -166.67% | -320.00% | -266.67% | -210.53% | -216.67% | -283.33% | -914.29% | -457.14% | -1,275.00% | -1,428.57% |
| Other Income | 0.05 | 0.30 | 0.95 | 0.28 | 0.19 | 0.04 | 0.04 | -0.05 | 0.06 | 10.55 | 0.96 | 0.76 | 1.08 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Depreciation | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.03 | 0.09 | 0.88 | 0.17 | 0.02 | -0.13 | -0.37 | -0.18 | -0.11 | 9.91 | 0.60 | -0.31 | 0.04 |
| Tax % | 133.33% | 0.00% | 25.00% | 35.29% | 3,100.00% | -7.69% | -186.49% | -16.67% | -9.09% | 0.50% | 23.33% | 0.00% | |
| Net Profit | -0.07 | 0.09 | 0.66 | 0.11 | -0.59 | -0.12 | 0.33 | -0.15 | -0.10 | 9.86 | 0.47 | -0.31 | 0.04 |
| EPS in Rs | |||||||||||||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 228.57% | 633.33% | -83.33% | -636.36% | 79.66% | 375.00% | -145.45% | 33.33% | 9960.00% | -95.23% | -165.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.76% | -716.67% | -553.03% | 716.02% | 295.34% | -520.45% | 178.79% | 9926.67% | -10055.23% | -70.72% |
Hindustan Agrigenetics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: October 10, 2025, 4:16 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 |
| Reserves | -2.44 | -2.35 | -1.69 | -1.63 | -2.22 | -2.48 | -2.16 | -2.30 | -2.40 | 7.46 | 7.93 | 7.62 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.98 | 1.01 | 0.23 | 0.15 | 0.16 | 0.22 | 0.28 | 0.85 | 6.19 | 0.50 | 0.42 | 0.38 |
| Total Liabilities | 2.94 | 3.06 | 2.94 | 2.92 | 2.34 | 2.14 | 2.52 | 2.95 | 8.19 | 12.36 | 12.75 | 12.40 |
| Fixed Assets | 0.36 | 0.36 | 0.35 | 0.34 | 0.35 | 0.36 | 0.36 | 0.35 | 0.35 | 0.05 | 0.19 | 0.16 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.35 | 1.45 | 1.57 | 1.58 | 1.59 | 1.38 | 0.21 | 1.35 | 1.75 | 0.85 | 1.97 | 3.64 |
| Other Assets | 1.23 | 1.25 | 1.02 | 1.00 | 0.40 | 0.40 | 1.95 | 1.25 | 6.09 | 11.46 | 10.59 | 8.60 |
| Total Assets | 2.94 | 3.06 | 2.94 | 2.92 | 2.34 | 2.14 | 2.52 | 2.95 | 8.19 | 12.36 | 12.75 | 12.40 |
Below is a detailed analysis of the balance sheet data for Hindustan Agrigenetics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 4.40 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.40 Cr..
- For Reserves, as of Mar 2025, the value is 7.62 Cr.. The value appears to be declining and may need further review. It has decreased from 7.93 Cr. (Mar 2024) to 7.62 Cr., marking a decrease of 0.31 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.38 Cr.. The value appears to be improving (decreasing). It has decreased from 0.42 Cr. (Mar 2024) to 0.38 Cr., marking a decrease of 0.04 Cr..
- For Total Liabilities, as of Mar 2025, the value is 12.40 Cr.. The value appears to be improving (decreasing). It has decreased from 12.75 Cr. (Mar 2024) to 12.40 Cr., marking a decrease of 0.35 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.16 Cr.. The value appears to be declining and may need further review. It has decreased from 0.19 Cr. (Mar 2024) to 0.16 Cr., marking a decrease of 0.03 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 3.64 Cr.. The value appears strong and on an upward trend. It has increased from 1.97 Cr. (Mar 2024) to 3.64 Cr., marking an increase of 1.67 Cr..
- For Other Assets, as of Mar 2025, the value is 8.60 Cr.. The value appears to be declining and may need further review. It has decreased from 10.59 Cr. (Mar 2024) to 8.60 Cr., marking a decrease of 1.99 Cr..
- For Total Assets, as of Mar 2025, the value is 12.40 Cr.. The value appears to be declining and may need further review. It has decreased from 12.75 Cr. (Mar 2024) to 12.40 Cr., marking a decrease of 0.35 Cr..
Notably, the Reserves (7.62 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.06 | -0.20 | -0.06 | -0.10 | -0.16 | -0.16 | -0.40 | -0.13 | -0.17 | -0.64 | -0.32 | -1.02 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Days | -5,170.83 | -5,353.33 | -730.00 | -243.33 | -365.00 | -608.33 | 883.68 | -4,501.67 | -36,925.83 | -1,668.57 | 730.00 | 11,543.12 |
| ROCE % | -3.51% | -2.00% | 33.61% | 0.00% | 0.81% | -1.95% | -13.46% | -5.99% | -7.80% | 144.88% | 2.07% | -3.53% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| Diluted EPS (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| Cash EPS (Rs.) | -0.61 | 1.15 | 22.41 | -0.21 | -0.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 27.32 | 27.65 | 26.58 | 4.17 | 4.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 27.32 | 28.02 | 26.95 | 4.55 | 4.77 |
| Revenue From Operations / Share (Rs.) | 0.17 | 2.35 | 24.43 | 0.28 | 0.13 |
| PBDIT / Share (Rs.) | -0.59 | 1.46 | 22.52 | -0.24 | -0.40 |
| PBIT / Share (Rs.) | -0.68 | 1.38 | 22.52 | -0.25 | -0.40 |
| PBT / Share (Rs.) | -0.69 | 1.38 | 22.52 | -0.25 | -0.40 |
| Net Profit / Share (Rs.) | -0.69 | 1.07 | 22.40 | -0.22 | -0.33 |
| PBDIT Margin (%) | -342.41 | 62.20 | 92.19 | -85.45 | -288.85 |
| PBIT Margin (%) | -388.97 | 58.64 | 92.17 | -87.40 | -295.28 |
| PBT Margin (%) | -399.09 | 58.64 | 92.17 | -87.40 | -295.28 |
| Net Profit Margin (%) | -395.59 | 45.44 | 91.71 | -76.62 | -238.42 |
| Return on Networth / Equity (%) | -2.53 | 3.85 | 84.29 | -5.28 | -7.52 |
| Return on Capital Employeed (%) | -2.42 | 4.91 | 83.54 | -5.53 | -8.59 |
| Return On Assets (%) | -2.45 | 3.68 | 79.74 | -1.18 | -4.94 |
| Asset Turnover Ratio (%) | 0.01 | 0.08 | 1.05 | 0.02 | 0.02 |
| Current Ratio (X) | 330.73 | 27.72 | 22.40 | 1.11 | 1.92 |
| Quick Ratio (X) | 330.73 | 27.72 | 22.40 | 1.11 | 1.92 |
| Interest Coverage Ratio (X) | -23.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | -26.77 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value (Cr.) | 24.41 | 13.01 | -8.02 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 316.56 | 12.59 | -0.74 | 0.00 | 0.00 |
| EV / EBITDA (X) | -92.45 | 20.24 | -0.80 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 383.23 | 21.77 | 0.20 | 0.00 | 0.00 |
| Price / BV (X) | 2.46 | 1.85 | 0.19 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 383.71 | 21.77 | 0.20 | 0.00 | 0.00 |
| EarningsYield | -0.01 | 0.02 | 4.44 | 0.00 | 0.00 |
After reviewing the key financial ratios for Hindustan Agrigenetics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.61. This value is below the healthy minimum of 3. It has decreased from 1.15 (Mar 24) to -0.61, marking a decrease of 1.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 27.65 (Mar 24) to 27.32, marking a decrease of 0.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 28.02 (Mar 24) to 27.32, marking a decrease of 0.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.17. It has decreased from 2.35 (Mar 24) to 0.17, marking a decrease of 2.18.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.59. This value is below the healthy minimum of 2. It has decreased from 1.46 (Mar 24) to -0.59, marking a decrease of 2.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.68. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.68, marking a decrease of 2.06.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.69, marking a decrease of 2.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 2. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
- For PBDIT Margin (%), as of Mar 25, the value is -342.41. This value is below the healthy minimum of 10. It has decreased from 62.20 (Mar 24) to -342.41, marking a decrease of 404.61.
- For PBIT Margin (%), as of Mar 25, the value is -388.97. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -388.97, marking a decrease of 447.61.
- For PBT Margin (%), as of Mar 25, the value is -399.09. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -399.09, marking a decrease of 457.73.
- For Net Profit Margin (%), as of Mar 25, the value is -395.59. This value is below the healthy minimum of 5. It has decreased from 45.44 (Mar 24) to -395.59, marking a decrease of 441.03.
- For Return on Networth / Equity (%), as of Mar 25, the value is -2.53. This value is below the healthy minimum of 15. It has decreased from 3.85 (Mar 24) to -2.53, marking a decrease of 6.38.
- For Return on Capital Employeed (%), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 10. It has decreased from 4.91 (Mar 24) to -2.42, marking a decrease of 7.33.
- For Return On Assets (%), as of Mar 25, the value is -2.45. This value is below the healthy minimum of 5. It has decreased from 3.68 (Mar 24) to -2.45, marking a decrease of 6.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.08 (Mar 24) to 0.01, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 3. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
- For Quick Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 2. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -23.78. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -23.78, marking a decrease of 23.78.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -26.77. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -26.77, marking a decrease of 26.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 24.41. It has increased from 13.01 (Mar 24) to 24.41, marking an increase of 11.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 316.56. This value exceeds the healthy maximum of 3. It has increased from 12.59 (Mar 24) to 316.56, marking an increase of 303.97.
- For EV / EBITDA (X), as of Mar 25, the value is -92.45. This value is below the healthy minimum of 5. It has decreased from 20.24 (Mar 24) to -92.45, marking a decrease of 112.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 383.23. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 383.23, marking an increase of 361.46.
- For Price / BV (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 1.85 (Mar 24) to 2.46, marking an increase of 0.61.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 383.71. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 383.71, marking an increase of 361.94.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.01, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hindustan Agrigenetics Ltd:
- Net Profit Margin: -395.59%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -2.42% (Industry Average ROCE: 3.57%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -2.53% (Industry Average ROE: 3.39%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -26.77
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 330.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 688 (Industry average Stock P/E: 346.37)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -395.59%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Floriculture | 806, Meghdoot, 94, Nehru Place, New Delhi Delhi 110019 | hindustanagrigenetics@gmail.com http://www.hindustanagrigenetics.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pranav Kapur | Chairman |
| Mr. Pritam Kapur | Director |
| Ms. Chandni Kapur | Director & CFO |
| Ms. Mannu Kohli | Director |
| Mr. Sunny Srivastava | Independent Director |
| Mr. Naren Parsai | Independent Director |
| Mr. Ravi Shankar Kolathur | Independent Director |
FAQ
What is the latest intrinsic value of Hindustan Agrigenetics Ltd?
The latest intrinsic value of Hindustan Agrigenetics Ltd is 0.00. Unfortunately, additional data is unavailable.
What is the Market Cap of Hindustan Agrigenetics Ltd?
The Market Cap of Hindustan Agrigenetics Ltd is 27.5 Cr..
What is the current Stock Price of Hindustan Agrigenetics Ltd as on 10 October 2025?
The current stock price of Hindustan Agrigenetics Ltd as on 10 October 2025 is 62.6.
What is the High / Low of Hindustan Agrigenetics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hindustan Agrigenetics Ltd stocks is 103/47.4.
What is the Stock P/E of Hindustan Agrigenetics Ltd?
The Stock P/E of Hindustan Agrigenetics Ltd is 688.
What is the Book Value of Hindustan Agrigenetics Ltd?
The Book Value of Hindustan Agrigenetics Ltd is .
What is the Dividend Yield of Hindustan Agrigenetics Ltd?
The Dividend Yield of Hindustan Agrigenetics Ltd is 0.00 %.
What is the ROCE of Hindustan Agrigenetics Ltd?
The ROCE of Hindustan Agrigenetics Ltd is 3.53 %.
What is the ROE of Hindustan Agrigenetics Ltd?
The ROE of Hindustan Agrigenetics Ltd is 3.61 %.
What is the Face Value of Hindustan Agrigenetics Ltd?
The Face Value of Hindustan Agrigenetics Ltd is 10.0.